Novo Nordisk to Provide 340B Refunds on Hemophilia Drugs

Novo Nordisk will issue 340B provider refunds for formulations of two hemophilia drugs, according to a HRSA manufacturer notice.
Novo Nordisk will issue its fifth round of refunds this year on prices charged to 340B providers. The latest are [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Legislation ‘Is Coming’ to Address Contract Pharmacy Restrictions, Hospital Advocate Says

Maureen Testoni headshot
Maureen Testoni, president and CEO of 340B Health, said she anticipates bipartisan legislation on drugmaker 340B contract pharmacy restrictions.
Months after it was expected, bipartisan legislation to prevent drugmaker restrictions on the use of contract pharmacies by 340B providers [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Drugmakers Highlight 340B Developments in Earnings Calls

Jean-Jacques Bienaime, CEO of drugmaker BioMarin, discussed the impact of 340B on pharmaceutical sales during an investor earnings call.
Pharmaceutical company executives discussed a range of 340B-related developments in recent third quarter investor calls. An executive for BioMarin Pharmaceutical, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Exclusive

Federal 340B Leader Moves On After 21 Months

Lt. Cmdr. Emeka Egwim headshot
U.S. Public Health Service Lieutenant Commander Emeka Egwim left his position as director of OPA at HRSA 21 months after he started.
U.S. Public Health Service Lieutenant Commander Emeka Egwim left his position as director of the federal office overseeing the 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Amid Record Drugmaker Refunds, No Adverse Audit Findings for Teva

Teva
The final HRSA manufacturer 340B program audit conducted in fiscal year 2023 had no adverse findings for Teva Pharmaceuticals.
The fifth and final fiscal year 2023 manufacturer audit by federal officials recently concluded with no adverse findings. Meanwhile, the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Four 340B Terminations, Eight Paybacks to Manufacturers in Latest Provider Audit Findings

HRSA provider audits
Federal auditors determined terminations from the 340B program were required for either covered entity sites or a contract pharmacy of two more 340B providers.
Federal auditors determined terminations from the 340B program were required for either covered entity sites or contract pharmacies of four [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Biogen Adds Drug with Narrow Approval to 340B Contract Pharmacy Restrictions

Biogen wordmark on building facade
Drugmaker Biogen recently added a third drug to its 340B contract pharmacy restrictions for hospitals.
Biopharmaceutical manufacturer Biogen recently expanded its contract pharmacy restrictions for hospitals to a third drug, after that medication garnered a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Reforms Needed, Says Former Presidential Candidate, Drug Industry Consultant

Howard Dean, a former Democratic presidential candidate who has consulted for the drug industry, said the 340B program is in need of reforms.
The 340B program has become “a multibillion-dollar boondoggle for hospital mega-chains” and needs reform, says Howard Dean, a one-time Democratic [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

‘Relentless’ 340B Policy Leader Among Coming Congressional Retirements

Rep. Abigail Spanberger (D-Va.), who has been a vocal advocate of provider access to the 340B program, is one of 38 members of Congress to announce their planned departures this year.
A congresswoman who has led legislative initiatives to bolster provider access to the 340B program was among 12 members of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Reforms Urged by Centrist Democrat Group with Drugmaker Ties

Darbin Wofford, a health policy advisor at Third Way, said his organization is urging Congressional Democrats to adopt 340B program reforms.
A center-left group that has received pharmaceutical industry funding is urging a series of 340B reforms that it hopes to [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live